
Sign up to save your podcasts
Or


As competitors publicly entered the race to produce a vaccine, drug giant Merck stayed quiet about its development plans. Now, the company has revealed it’s working on two vaccines and a treatment pill -- emerging as a frontrunner in the development contest. Although the company has refused to give firm timelines for its research, it has pledged to make its vaccines and pill available globally, if they're successful. Riley Griffin talked with Merck Chief Executive Kenneth C. Frazier about the company's plans.
See omnystudio.com/listener for privacy information.
By Bloomberg3.7
805805 ratings
As competitors publicly entered the race to produce a vaccine, drug giant Merck stayed quiet about its development plans. Now, the company has revealed it’s working on two vaccines and a treatment pill -- emerging as a frontrunner in the development contest. Although the company has refused to give firm timelines for its research, it has pledged to make its vaccines and pill available globally, if they're successful. Riley Griffin talked with Merck Chief Executive Kenneth C. Frazier about the company's plans.
See omnystudio.com/listener for privacy information.

78,678 Listeners

32,092 Listeners

6,763 Listeners

28,944 Listeners

16,195 Listeners

2,682 Listeners

405 Listeners

2,189 Listeners

1,982 Listeners

420 Listeners

12,227 Listeners

17,603 Listeners

969 Listeners

112,220 Listeners

197 Listeners

30 Listeners

10,183 Listeners

5 Listeners

58 Listeners

233 Listeners

232 Listeners

65 Listeners

75 Listeners

86 Listeners

403 Listeners

18 Listeners

12 Listeners

7 Listeners

2 Listeners

114 Listeners

1,146 Listeners

184 Listeners